{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:46:01Z","timestamp":1784940361334,"version":"3.55.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100009321","name":"icare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009321","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001170","name":"Cancer Council Western Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001170","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.lungcan.2019.12.018","type":"journal-article","created":{"date-parts":[[2019,12,31]],"date-time":"2019-12-31T08:54:04Z","timestamp":1577782444000},"page":"87-92","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["A phase II trial of single oral FGF inhibitor, AZD4547, as second or third line therapy in malignant pleural mesothelioma"],"prefix":"10.1016","volume":"140","author":[{"given":"Wei-Sen","family":"Lam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenette","family":"Creaney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred K.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wee Loong","family":"Chin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeevan","family":"Muruganandan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sukanya","family":"Arunachalam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary S.","family":"Attia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Read","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Millward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Spiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aron","family":"Chakera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0036-511X","authenticated-orcid":false,"given":"Y.C.","family":"Gary Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna K.","family":"Nowak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"July (14)","key":"10.1016\/j.lungcan.2019.12.018_bib0005","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"April (10026)","key":"10.1016\/j.lungcan.2019.12.018_bib0010","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"issue":"May (2)","key":"10.1016\/j.lungcan.2019.12.018_bib0015","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.lungcan.2007.08.031","article-title":"Retreatment with pemetrexed-based chemotherapy in malignant pleural mesothelioma (MPM): a second line treatment option","volume":"60","author":"Razak","year":"2008","journal-title":"Lung Cancer"},{"issue":"June (3)","key":"10.1016\/j.lungcan.2019.12.018_bib0020","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.lungcan.2014.03.006","article-title":"Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma","volume":"84","author":"Zauderer","year":"2014","journal-title":"Lung Cancer"},{"issue":"January (1)","key":"10.1016\/j.lungcan.2019.12.018_bib0025","doi-asserted-by":"crossref","first-page":"S294","DOI":"10.1016\/j.jtho.2016.11.302","article-title":"OA13.03 long-term overall survival for patients with malignant pleural mesothelioma on pembrolizumab enrolled in KEYNOTE-028","volume":"12","author":"Alley","year":"2017","journal-title":"J. Thorac. Oncol."},{"issue":"March (3)","key":"10.1016\/j.lungcan.2019.12.018_bib0030","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S2213-2600(18)30420-X","article-title":"Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial","volume":"7","author":"Disselhorst","year":"2019","journal-title":"Lancet Respir. Med."},{"issue":"February (2)","key":"10.1016\/j.lungcan.2019.12.018_bib0035","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(18)30765-4","article-title":"Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial","volume":"20","author":"Scherpereel","year":"2019","journal-title":"Lancet Oncol."},{"issue":"March (3)","key":"10.1016\/j.lungcan.2019.12.018_bib0040","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nrd2792","article-title":"The FGF family: biology, pathophysiology and therapy","volume":"8","author":"Beenken","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"issue":"March (2)","key":"10.1016\/j.lungcan.2019.12.018_bib0045","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/med.21288","article-title":"FGF receptors: cancer biology and therapeutics","volume":"34","author":"Katoh","year":"2014","journal-title":"Med. Res. Rev."},{"issue":"October (10)","key":"10.1016\/j.lungcan.2019.12.018_bib0050","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1158\/1541-7786.MCR-14-0038","article-title":"Non-amplified FGFR1 is a growth driver in malignant pleural mesothelioma","volume":"12","author":"Marek","year":"2014","journal-title":"Mol. Cancer Res."},{"issue":"June (26)","key":"10.1016\/j.lungcan.2019.12.018_bib0055","doi-asserted-by":"crossref","first-page":"39861","DOI":"10.18632\/oncotarget.9515","article-title":"Inhibition of FGF\/FGFR autocrine signaling in mesothelioma with the FGF ligand trap, FP-1039\/GSK3052230","volume":"7","author":"Blackwell","year":"2016","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.lungcan.2019.12.018_bib0060","first-page":"S90","article-title":"Inhibition of fibroblast growth factor-9 significantly retards tumour growth in two murine models of malignant mesothelioma","volume":"19","author":"Lansley","year":"2014","journal-title":"Respirology"},{"issue":"April (8)","key":"10.1016\/j.lungcan.2019.12.018_bib0065","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1158\/0008-5472.CAN-11-3034","article-title":"AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family","volume":"72","author":"Gavine","year":"2012","journal-title":"Cancer Res."},{"issue":"May (4)","key":"10.1016\/j.lungcan.2019.12.018_bib0070","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.tranon.2017.03.001","article-title":"Antitumor effect of AZD4547 in a fibroblast growth factor receptor 2\u2013Amplified gastric Cancer patient\u2013Derived cell model","volume":"10","author":"Jang","year":"2017","journal-title":"Transl. Oncol."},{"issue":"Septrmber (18)","key":"10.1016\/j.lungcan.2019.12.018_bib0075","doi-asserted-by":"crossref","first-page":"5366","DOI":"10.1158\/1078-0432.CCR-17-0645","article-title":"A phase ib open-label multicenter study of AZD4547 in patients with advanced squamous cell lung cancers","volume":"23","author":"Paik","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"February (2)","key":"10.1016\/j.lungcan.2019.12.018_bib0080","first-page":"2303","article-title":"A potential novel therapy for FGFR1-amplified pancreatic cancer with bone metastasis, screened by next-generation sequencing and a patient-derived xenograft model","volume":"17","author":"Guan","year":"2019","journal-title":"Oncol. Lett."},{"issue":"April (8 Supplement)","key":"10.1016\/j.lungcan.2019.12.018_bib0085","doi-asserted-by":"crossref","first-page":"LB-145","DOI":"10.1158\/1538-7445.AM2013-LB-145","article-title":"Noll R van der, Stockman PK, et al. Abstract LB-145: Results of a phase I study of AZD4547, an inhibitor of fibroblast growth factor receptor (FGFR), in patients with advanced solid tumors","volume":"73","author":"Andre","year":"2013","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.lungcan.2019.12.018_bib0090","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s10637-016-0416-x","article-title":"Safety, tolerability and pharmacokinetics of the fibroblast growth factor receptor inhibitor AZD4547 in Japanese patients with advanced solid tumours: a Phase I study","volume":"35","author":"Saka","year":"2017","journal-title":"Invest. New Drugs"},{"issue":"February (2)","key":"10.1016\/j.lungcan.2019.12.018_bib0095","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/annonc\/mdh059","article-title":"Modified RECIST criteria for assessment of response in malignant pleural mesothelioma","volume":"15","author":"Byrne","year":"2004","journal-title":"Ann. Oncol."},{"issue":"October (2)","key":"10.1016\/j.lungcan.2019.12.018_bib0100","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1093\/toxsci\/kft161","article-title":"Pan-FGFR inhibition leads to blockade of FGF23 signaling, soft tissue mineralization, and cardiovascular dysfunction","volume":"135","author":"Yanochko","year":"2013","journal-title":"Toxicol. Sci."},{"issue":"1","key":"10.1016\/j.lungcan.2019.12.018_bib0105","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1158\/1078-0432.CCR-17-1172","article-title":"Comprehensive pharmacogenomic profiling of malignant pleural mesothelioma identifies a subgroup sensitive to FGFR inhibition","volume":"24","author":"Quispel-Janssen","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2019.12.018_bib0110","series-title":"R: a Language and Environment for Statistical Computing","author":"R Core Team","year":"2013"},{"issue":"June (12)","key":"10.1016\/j.lungcan.2019.12.018_bib0115","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1158\/1078-0432.CCR-14-2329","article-title":"Targeting FGFR signaling in Cancer","volume":"21","author":"Touat","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.lungcan.2019.12.018_bib0120","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/j.ophtha.2017.05.038","article-title":"Clinical and Morphologic Characteristics of MEK Inhibitor-Associated Retinopathy: Differences from Central Serous Chorioretinopathy","volume":"124","author":"Francis","year":"2017","journal-title":"Ophthalmology"},{"issue":"September (9)","key":"10.1016\/j.lungcan.2019.12.018_bib0125","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/j.ophtha.2015.05.027","article-title":"Serous retinopathy associated with mitogen-activated protein kinase kinase inhibition (Binimetinib) for metastatic cutaneous and uveal melanoma","volume":"122","author":"van Dijk","year":"2015","journal-title":"Ophthalmology"},{"issue":"August (8)","key":"10.1016\/j.lungcan.2019.12.018_bib0130","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1001\/jamaophthalmol.2016.0090","article-title":"Subretinal fluid associated with MEK inhibitor use in the treatment of systemic Cancer","volume":"134","author":"Weber","year":"2016","journal-title":"JAMA Ophthalmol."},{"issue":"November (7)","key":"10.1016\/j.lungcan.2019.12.018_bib0135","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1111\/aos.13677","article-title":"Pimasertib-associated ophthalmological adverse events","volume":"96","author":"van Dijk","year":"2018","journal-title":"Acta Ophthalmol."},{"issue":"15suppl","key":"10.1016\/j.lungcan.2019.12.018_bib0140","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1200\/JCO.2017.35.15_suppl.1059","article-title":"RADICAL trial: a phase Ib\/IIa study to assess the safety and efficacy of AZD4547 in combination with either anastrozole or letrozole in ER positive breast cancer patients progressing on these aromatase inhibitors (AIs)","volume":"35","author":"Seckl","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"May (15suppl)","key":"10.1016\/j.lungcan.2019.12.018_bib0145","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1200\/jco.2014.32.15_suppl.2620","article-title":"A phase 1 expansion cohort of the fibroblast growth factor receptor (FGFR) inhibitor AZD4547 in patients (pts) with advanced gastric (GC) and gastroesophageal (GOJ) cancer","volume":"32","author":"Arkenau","year":"2014","journal-title":"J. Clin. Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016950021930786X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016950021930786X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:36:22Z","timestamp":1759235782000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016950021930786X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":29,"alternative-id":["S016950021930786X"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2019.12.018","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase II trial of single oral FGF inhibitor, AZD4547, as second or third line therapy in malignant pleural mesothelioma","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2019.12.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}